Patents by Inventor Leena Ravindra YEOLEKAR

Leena Ravindra YEOLEKAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
    Patent number: 11660333
    Abstract: Stable lyophilized immunogenic compositions include inter alia live attenuated recombinant flaviviruses, more preferably live attenuated recombinant dengue viruses, at least one carbohydrate, at least one amino acid and is particularly amenable to rapid freeze-drying treatments wherein, the composition preserves desired characteristics of a virus, including virus viability, immunogenicity and stability. The immunogenic composition is devoid of preservatives, polymers and surfactants. The methods for manufacturing the stable lyophilized immunogenic compositions are also provided.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 30, 2023
    Assignee: Serum Institute of India Private Limited
    Inventors: Rajeev Mhalasakant Dhere, Leena Ravindra Yeolekar, Vinit Kumar, Rohit Bapurav Sonar, Sandeep Dinkar Baraskar, Rajeev Mehla, Shashikant Janardan Ghodekar, Cyrus Soli Poonawalla, Adar Cyrus Poonawalla
  • LIVE ATTENUATED INFLUENZA VACCINE COMPOSITION AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20220211837
    Abstract: The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants.
    Type: Application
    Filed: February 7, 2020
    Publication date: July 7, 2022
    Inventors: Rajeev Mhalasakant DHERE, Leena Ravindra Yeolekar, Milan Shomenath Ganguly, Parikshit Dharampal Tyagi, Umesh Gorakh Sagar, Swapnil Prabhakar Narale, Yashodhan Dilip Anaspure, Sham Ramdas Tupe
  • STABLE VACCINE COMPOSITIONS COMPRISING INTER ALIA LIVE ATTENUATED RECOMBINANT FLAVIVIRUS AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20210187092
    Abstract: Stable lyophilized immunogenic compositions include inter alia live attenuated recombinant flaviviruses, more preferably live attenuated recombinant dengue viruses, at least one carbohydrate, at least one amino acid and is particularly amenable to rapid freeze-drying treatments wherein, the composition preserves desired characteristics of a virus, including virus viability, immunogenicity and stability. The immunogenic composition is devoid of preservatives, polymers and surfactants. The methods for manufacturing the stable lyophilized immunogenic compositions are also provided.
    Type: Application
    Filed: October 10, 2018
    Publication date: June 24, 2021
    Inventors: Rajeev Mhalasakant DHERE, Leena Ravindra YEOLEKAR, Vinit KUMAR, Rohit Bapurav SONAR, Sandeep Dinkar BARASKAR, Rajeev MEHLA, Shashikant Janardan GHODEKAR